Nina Onishchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina Onishchenko has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alla O. Nikolskaya
The Shumakov National Medical Research Center of Transplantology and Artificial Organs, 123182 Moscow, Russia
4 shared publications - Murat Shagidulin
Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow 123182, Russia
4 shared publications - Artem A. Venediktov
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Egor A. Kuzmin
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Gennadii A. Piavchenko
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Ksenia S. Pokidova
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5340
Treatment of Chronic Liver Fibrosis: Adipose and Bone Marrow Mesenchymal Stem Cells
Liver fibrosis is a severe but common disease without an easy-to-access option for efficient treatment. Mesenchymal stem cells (MSCs) of different origins have been tested for antifibrotic effects in vitro, in vivo, and in clinical studies over the two last decades, although the comparative efficiency of different subtypes remains not fully understood, especially for long-term survival. In this study, we aimed to compare the long-time persistence of favorable effects in male Wistar rats with liver fibrosis treated using MSCs derived from white adipose tissue (AdMSCs) and bone marrow (BMSCs). Liver fibrosis was induced by carbon tetrachloride. We studied the survival rate; oxidative index, assessed via laser Doppler flowmetry; hepatic markers in blood plasma—albumin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase; the ratio of liver to body mass; histological parameters—the number of adipocytes, lymphocytes, siderophages, and Ki67+ cells; and the relative areas of connective tissue proper and reticular fibers. Extra mortality was only typical for fibrotic animals subjected to the sham treatment in the first two weeks. Up to Day 270 of this study, both MSC-treated groups showed barely any differences from animals undergoing the sham treatment in terms of the oxidative index and blood markers, although AdMSC-treated rats presented a more favorable histological pattern than BMSC-treated ones, considering the relative area of reticular fibers and the Ki67 cell count. This study suggests that AdMSC treatments may be more appropriate than BMSC treatments in animal liver fibrosis models, with the results showing better potential for liver tissue regeneration 9 months after treatment.
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5340
Open AccessTreatment of Chronic Liver Fibrosis: Adipose and Bone Marrow Mesenchymal Stem Cells
Liver fibrosis is a severe but common disease without an easy-to-access option for efficient treatment. Mesenchymal stem cells (MSCs) of different origins have been tested for antifibrotic effects in vitro, in vivo, and in clinical studies over the two last decades, although the comparative efficiency of different subtypes remains not fully understood, especially for long-term survival. In this study, we aimed to compare the long-time persistence of favorable effects in male Wistar rats with liver fibrosis treated using MSCs derived from white adipose tissue (AdMSCs) and bone marrow (BMSCs). Liver fibrosis was induced by carbon tetrachloride. We studied the survival rate; oxidative index, assessed via laser Doppler flowmetry; hepatic markers in blood plasma—albumin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase; the ratio of liver to body mass; histological parameters—the number of adipocytes, lymphocytes, siderophages, and Ki67+ cells; and the relative areas of connective tissue proper and reticular fibers. Extra mortality was only typical for fibrotic animals subjected to the sham treatment in the first two weeks. Up to Day 270 of this study, both MSC-treated groups showed barely any differences from animals undergoing the sham treatment in terms of the oxidative index and blood markers, although AdMSC-treated rats presented a more favorable histological pattern than BMSC-treated ones, considering the relative area of reticular fibers and the Ki67 cell count. This study suggests that AdMSC treatments may be more appropriate than BMSC treatments in animal liver fibrosis models, with the results showing better potential for liver tissue regeneration 9 months after treatment.
- Open Access
- 27 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (19) , 10471
Mesenchymal Stem Cells in Liver Fibrosis: A Dose-Dependent Recovery
Mesenchymal stem cells (MSCs) are known to assist liver regeneration. In this study, we show a dose-dependent mode of recovery from liver fibrosis after intravenous injections of MSCs. Male Wistar rats experienced a 42-day-long modeling of liver fibrosis via CCl4 poisoning and received either a single injection of 2.5 × 106 MSCs on Day 3 after the last CCl4 dose or two MSC injections on Days 3 and 10. We dynamically monitored levels of liver cytolysis markers and cytokines in the venous blood and performed a histological study of Mallory-stained liver sections. All experimental groups experienced a nearly complete recovery of biochemical markers up to 4 weeks after the end of CCl4 administration, although we observed anti-inflammatory changes in the cytokine levels only in animals treated by two MSC injections. Histological study revealed minor signs of liver damage up to Day 90 in animals receiving two MSC doses with worse pathology in those who received a single MSC dose. Morphometric values stayed consistent with visual data, demonstrating a significantly larger number of binuclear hepatocytes, a smaller number of false lobules, and a lesser area of connective tissue proper in animals treated by two MSC injections. Our results reflect MSC grafting in applied doses to affect liver fibrosis in a dose-dependent mode. These findings provide a deeper understanding of MSC action in liver fibrosis, and the doses applied may serve as a milestone for further studies in humans.
- 27 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (19) , 10471
Open AccessMesenchymal Stem Cells in Liver Fibrosis: A Dose-Dependent Recovery
Mesenchymal stem cells (MSCs) are known to assist liver regeneration. In this study, we show a dose-dependent mode of recovery from liver fibrosis after intravenous injections of MSCs. Male Wistar rats experienced a 42-day-long modeling of liver fibrosis via CCl4 poisoning and received either a single injection of 2.5 × 106 MSCs on Day 3 after the last CCl4 dose or two MSC injections on Days 3 and 10. We dynamically monitored levels of liver cytolysis markers and cytokines in the venous blood and performed a histological study of Mallory-stained liver sections. All experimental groups experienced a nearly complete recovery of biochemical markers up to 4 weeks after the end of CCl4 administration, although we observed anti-inflammatory changes in the cytokine levels only in animals treated by two MSC injections. Histological study revealed minor signs of liver damage up to Day 90 in animals receiving two MSC doses with worse pathology in those who received a single MSC dose. Morphometric values stayed consistent with visual data, demonstrating a significantly larger number of binuclear hepatocytes, a smaller number of false lobules, and a lesser area of connective tissue proper in animals treated by two MSC injections. Our results reflect MSC grafting in applied doses to affect liver fibrosis in a dose-dependent mode. These findings provide a deeper understanding of MSC action in liver fibrosis, and the doses applied may serve as a milestone for further studies in humans.
- Open Access
- 30 March 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (7) , 3782
Hematopoietic Stem Cells of Bone Marrow and Their Total RNA in Rat Liver Regeneration
Hematopoietic stem cells derived from bone marrow are known to induce tissue repair. Their mechanisms to induce liver regeneration are not clear and may have numerous adverse effects. We compared the regenerative potential of intact hematopoietic stem cells (iHSCs), their total RNA, and apoptotic hematopoietic stem cells (aHSCs) in liver damage. Male Wistar rats (n = 40 per group) experienced a 75% liver resection and received single intraperitoneal injections of saline (control group), iHSCs, aHSCs, or total RNA of iHSCs. We recorded animal survival, liver mass, blood markers of liver cell lysis and function (albumin, aminotransferases, alkaline phosphatase), and liver histological features: mitotic index and expression of markers for proliferation and apoptosis (caspase-9, caspase-3, and Ki-67). We assessed the survival with the log-rank test and used Wilcoxon and t tests for the other parameters. Animals of all HSC- or RNA-treated groups survived until the end of the experiment with full blood marker recovery (p = 0.037). The liver mass enlarged mostly after apoptotic hematopoietic stem cells and total RNA. Mitotic index peaked in the group of total RNA with a lower but earlier increase for the aHSC group, and Ki-67 proliferation for the total RNA group was the highest (all the differences were significant with p values ˂ 0.05). We found the aHSCs and total RNA of iHSC group to be the most efficient for liver reparation. Total RNA from HSCs is preferred for further liver regeneration studies.
- 30 March 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (7) , 3782
Open AccessHematopoietic Stem Cells of Bone Marrow and Their Total RNA in Rat Liver Regeneration
Hematopoietic stem cells derived from bone marrow are known to induce tissue repair. Their mechanisms to induce liver regeneration are not clear and may have numerous adverse effects. We compared the regenerative potential of intact hematopoietic stem cells (iHSCs), their total RNA, and apoptotic hematopoietic stem cells (aHSCs) in liver damage. Male Wistar rats (n = 40 per group) experienced a 75% liver resection and received single intraperitoneal injections of saline (control group), iHSCs, aHSCs, or total RNA of iHSCs. We recorded animal survival, liver mass, blood markers of liver cell lysis and function (albumin, aminotransferases, alkaline phosphatase), and liver histological features: mitotic index and expression of markers for proliferation and apoptosis (caspase-9, caspase-3, and Ki-67). We assessed the survival with the log-rank test and used Wilcoxon and t tests for the other parameters. Animals of all HSC- or RNA-treated groups survived until the end of the experiment with full blood marker recovery (p = 0.037). The liver mass enlarged mostly after apoptotic hematopoietic stem cells and total RNA. Mitotic index peaked in the group of total RNA with a lower but earlier increase for the aHSC group, and Ki-67 proliferation for the total RNA group was the highest (all the differences were significant with p values ˂ 0.05). We found the aHSCs and total RNA of iHSC group to be the most efficient for liver reparation. Total RNA from HSCs is preferred for further liver regeneration studies.
- Open Access
- 16 April 2024
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
- Vol. 68 (1) , 98-108
Динамика состояния клеток крови и костного мозга у мышей при прогрессирующем развитии сахарного диабета 2 типа
Цель работы: изучить динамику состояния клеток крови и костного мозга при прогрессирующем развитии сахарного диабета 2 типа (СД2) в зависимости от степени тяжести нарушений окислительно-восстановительных процессов (ОВП) в тканях организма. Методика. Использована генетическая модель СД2 у мутантных мышей – db/db (опытная группа n=30). Контролем слу жили здоровые мыши той же линии – db/+m (n=10) и линии B10 (n=5). В течение 6–6,5 мес контролировали: динамику кли нических показателей (глюкоза крови, гликозилированный гемоглобин, масса тела) и состояние ОВП в тканях организма по уровню активности НАДН, ФАД и показателю окислительного метаболизма (ПОМ) с помощью аппарата «Лазма-СТ». В течение того же срока исследовали состояние клеток крови (эритроциты, лейкоциты, тромбоциты) и костного мозга. Ста тистическую обработку результатов проводили с предварительным использованием теста Шапиро–Уилкса; достоверность различий с контролем оценивали с помощью параметрического t – критерия Стьюдента, при р<0,05. Результаты. В развитии СД2 выявлено 3 стадии прогрессирующего нарушения метаболизма и ОВП: I – стадия адаптации (1,0-2,0 мес); II – стадия прогрессирующей дисадаптации (2,5-4,5 мес); III – стадия декомпенсации (5,0-6,5 мес). Установлено, что уже в I стадии у мышей db/db снижалось содержание эритроцитов, Hb г/л и лейкоцитов. Во II и особенно в III стадиях происходило повышение тромбоцитов, нейтрофилов, моноцитов, эозинофилов, снижение лимфоцитов. В костном мозге у мышей db/db уже в I, но особенно в III стадии определялось снижение доли живых и повышение количества поврежден ных клеток, преимущественно за счёт апонекротических клеток. Заключение. По мере прогрессирования СД2 и выраженного снижения эффективности ОВП, особенно на III стадии – в организме тормозятся процессы кроветворения и усиливаются нарушения в соотношении клеточных популяций нейтро филы/лимфоциты, что свидетельствует о развитии тяжёлой гипоксии, активации системной воспалительной реакции и торможении репаративных процессов, создающих условия для развития опасных осложнений. Aim: to study the dynamics of changes in the blood and bone marrow cells during the progression of type 2 diabetes mellitus (DM2) depending on the severity of redox (RO) disorders in tissues. Methods. A genetic model of DM2 in mutant db/db mice (experimental group, n=30) was used. The control group consisted of the same mouse strain, db/+m (n=10), and the B10 strain (n=5). Time-related changes in clinical variables (blood glucose, HbA1c, body weight) and the tissue RO status were monitored for 6-6.5 months. The RO status was evaluated by the NADH concentration, FAD activ ity, and the indicator of oxidative metabolism (IOM) using a Lasma-ST apparatus. During the same period, the condition of blood cells (erythrocytes, leukocytes, platelets) and bone marrow cells was examined. Statistical analysis was performed with a preliminary Shap iro-Wilks normality test followed by the parametric Student’s t-test. Differences from the control were considered significant at p<0.05. Results. During the development of DM2, three stages of progressive metabolic and RO disorders were identified: I: stage of adap tation (1.0-2.0 months); II, stage of progressive maladaptation (2.5-4.5 months); III, stage of decompensation (5.0-6.5 months). In db/db mice already at stage I, erythrocytes, Hb and leukocytes were decreased. At stages II and especially III, platelets, neutrophils, monocytes, and eosinophils were increased whereas lymphocytes were reduced. In the bone marrow of db/db mice, already in stage I, but even more in stage III, the proportion of living cells was decreased and the proportion of damaged cells was increased, primarily due to the contribution of aponecrotic cells. Conclusion. With the progression of DM2 and a pronounced decrease in the effectiveness of RO processes, especially at stage III, the hematopoietic processes were inhibited and the disorders in the neutrophil/lymphocyte cell population ratio intensified. This indicates the development of severe hypoxia, activation of a systemic inflammatory response, and inhibition of reparative processes that create conditions for development of dangerous complications.
- 16 April 2024
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
- Vol. 68 (1) , 98-108
Open AccessДинамика состояния клеток крови и костного мозга у мышей при прогрессирующем развитии сахарного диабета 2 типа
Цель работы: изучить динамику состояния клеток крови и костного мозга при прогрессирующем развитии сахарного диабета 2 типа (СД2) в зависимости от степени тяжести нарушений окислительно-восстановительных процессов (ОВП) в тканях организма. Методика. Использована генетическая модель СД2 у мутантных мышей – db/db (опытная группа n=30). Контролем слу жили здоровые мыши той же линии – db/+m (n=10) и линии B10 (n=5). В течение 6–6,5 мес контролировали: динамику кли нических показателей (глюкоза крови, гликозилированный гемоглобин, масса тела) и состояние ОВП в тканях организма по уровню активности НАДН, ФАД и показателю окислительного метаболизма (ПОМ) с помощью аппарата «Лазма-СТ». В течение того же срока исследовали состояние клеток крови (эритроциты, лейкоциты, тромбоциты) и костного мозга. Ста тистическую обработку результатов проводили с предварительным использованием теста Шапиро–Уилкса; достоверность различий с контролем оценивали с помощью параметрического t – критерия Стьюдента, при р<0,05. Результаты. В развитии СД2 выявлено 3 стадии прогрессирующего нарушения метаболизма и ОВП: I – стадия адаптации (1,0-2,0 мес); II – стадия прогрессирующей дисадаптации (2,5-4,5 мес); III – стадия декомпенсации (5,0-6,5 мес). Установлено, что уже в I стадии у мышей db/db снижалось содержание эритроцитов, Hb г/л и лейкоцитов. Во II и особенно в III стадиях происходило повышение тромбоцитов, нейтрофилов, моноцитов, эозинофилов, снижение лимфоцитов. В костном мозге у мышей db/db уже в I, но особенно в III стадии определялось снижение доли живых и повышение количества поврежден ных клеток, преимущественно за счёт апонекротических клеток. Заключение. По мере прогрессирования СД2 и выраженного снижения эффективности ОВП, особенно на III стадии – в организме тормозятся процессы кроветворения и усиливаются нарушения в соотношении клеточных популяций нейтро филы/лимфоциты, что свидетельствует о развитии тяжёлой гипоксии, активации системной воспалительной реакции и торможении репаративных процессов, создающих условия для развития опасных осложнений. Aim: to study the dynamics of changes in the blood and bone marrow cells during the progression of type 2 diabetes mellitus (DM2) depending on the severity of redox (RO) disorders in tissues. Methods. A genetic model of DM2 in mutant db/db mice (experimental group, n=30) was used. The control group consisted of the same mouse strain, db/+m (n=10), and the B10 strain (n=5). Time-related changes in clinical variables (blood glucose, HbA1c, body weight) and the tissue RO status were monitored for 6-6.5 months. The RO status was evaluated by the NADH concentration, FAD activ ity, and the indicator of oxidative metabolism (IOM) using a Lasma-ST apparatus. During the same period, the condition of blood cells (erythrocytes, leukocytes, platelets) and bone marrow cells was examined. Statistical analysis was performed with a preliminary Shap iro-Wilks normality test followed by the parametric Student’s t-test. Differences from the control were considered significant at p<0.05. Results. During the development of DM2, three stages of progressive metabolic and RO disorders were identified: I: stage of adap tation (1.0-2.0 months); II, stage of progressive maladaptation (2.5-4.5 months); III, stage of decompensation (5.0-6.5 months). In db/db mice already at stage I, erythrocytes, Hb and leukocytes were decreased. At stages II and especially III, platelets, neutrophils, monocytes, and eosinophils were increased whereas lymphocytes were reduced. In the bone marrow of db/db mice, already in stage I, but even more in stage III, the proportion of living cells was decreased and the proportion of damaged cells was increased, primarily due to the contribution of aponecrotic cells. Conclusion. With the progression of DM2 and a pronounced decrease in the effectiveness of RO processes, especially at stage III, the hematopoietic processes were inhibited and the disorders in the neutrophil/lymphocyte cell population ratio intensified. This indicates the development of severe hypoxia, activation of a systemic inflammatory response, and inhibition of reparative processes that create conditions for development of dangerous complications.
- 15 September 2017
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 12 (3) , 265
Vliyanie kletochnogo sostava bioinzhenernykh konstruktsiy pecheni na korrektsiyu i lechenie khronicheskoy pechenochnoy nedostatochnosti
Vliyanie kletochnogo sostava bioinzhenernykh konstruktsiy pecheni na korrektsiyu i lechenie khronicheskoy pechenochnoy nedostatochnosti Влияние клеточного состава биоинженерных конструкций печени на коррекцию и лечение хронической печеночной недостаточности
- 15 September 2017
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 12 (3) , 265
Vliyanie kletochnogo sostava bioinzhenernykh konstruktsiy pecheni na korrektsiyu i lechenie khronicheskoy pechenochnoy nedostatochnosti
Vliyanie kletochnogo sostava bioinzhenernykh konstruktsiy pecheni na korrektsiyu i lechenie khronicheskoy pechenochnoy nedostatochnosti Влияние клеточного состава биоинженерных конструкций печени на коррекцию и лечение хронической печеночной недостаточности